Marksans Pharma Secures USFDA Nod for Generic Version of Clartin Tablet
Marksans' product, Loratadine Tablets USP 10 mg are indicated for the treatment of allergic rhinitis.
Mumbai: Marksans Pharma Limited has announced the final approval of its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg from the USFDA.
Loratadine Tablets USP 10 mg are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use.
This product is generic version of Clartin tablet in the same strength of Bayer Healthcare.
Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies.
Also Read: Marksans Pharma arm gets UK MHRA marketing authorization for oral emergency contraceptive pill
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.
The Company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Upper respiratory and Gastroenterological. The Company is marketing these products globally.
